Copaxone 40mg Generic At-Risk Launch Anticipated As Soon As February
Executive Summary
Teva is seeking injunction to block generic entry after court rules four patents on the three-times-a-week dosage are invalid; analysts expect launch soon after FDA approves an ANDA, with Sandoz/Momenta generic the likely leader.
You may also be interested in...
He's Handled More ANDA Cases Than Anyone, And Now He's Retiring: Judge Sleet Reflects On His Career
In an interview with the Pink Sheet, Delaware District Judge Sleet discusses patent reform fallout and major issues facing district courts.
He's Handled More ANDA Cases Than Anyone, And Now He's Retiring: Judge Sleet Reflects On His Career
In an interview with the Pink Sheet, Delaware District Judge Sleet discusses patent reform fallout and major issues facing district courts.
Copaxone 40mg Generic: FDA Exceeds Mylan's Expectations
FDA approves the product well before Mylan's prediction of 2018.